Expanded extracolonic tumor spectrum in MUTYH-associated polyposis

Area of Science:

• Genetics
• Oncology
• Gastroenterology

Background:

• MUTYH-associated polyposis (MAP) presents a high lifetime risk of colorectal cancer (up to 100%).
• Extracolonic manifestations in MAP patients have not been systematically evaluated.
• Understanding extracolonic risks is crucial for comprehensive patient management.

Purpose of the Study:

• To systematically evaluate the spectrum and incidence of extracolonic manifestations in MUTYH-associated polyposis.
• To determine the cumulative lifetime risk of various cancers in MAP patients.
• To compare cancer risks in MAP patients with the general population.

Main Methods:

• A European multicenter study recruited a large cohort of MAP patients (276 cases from 181 families).
• Data on extracolonic tumor spectrum and incidence were collected.
• Standardized incidence ratios (SIRs) were calculated to compare risks with the general population.

Main Results:

• Duodenal polyposis occurred in 17% of cases, with a 4% lifetime risk of duodenal cancer (SIR: 129).
• Overall extraintestinal malignancy incidence was nearly double that of the general population (SIR: 1.9), with a 38% lifetime risk.
• Significant increases in ovarian (SIR: 5.7), bladder (SIR: 7.2), and skin (SIR: 2.8) cancers were observed, along with a trend for breast cancer.
• Median onset for these cancers ranged from 51 to 61 years.
• Sebaceous gland tumors were noted in 5 patients, characteristic of the Muir-Torre variant.

Conclusions:

• Patients with MAP exhibit elevated risks for several extraintestinal malignancies.
• The observed cancer spectrum and advanced age at onset suggest limited benefit from intensive surveillance beyond standard endoscopic screening.
• Management strategies should consider the specific extracolonic risks associated with MAP.